First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

Méndez, José; Fernández, Mercedes Salgado; Gómez, Jesús García; Augusto, Mari Luz Pellón; Rúa, Marta Covela; Aldana, G. Quintero; Montes, Ana; M, Lopez; Ayerbes, Manuel Valladares; Fernández, Mónica Jorge; Villarroel, Paula González; Reinoso, Carlos Romero; Vázquez, Manuel Ramos

doi:10.1016/j.jgo.2020.06.003

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The three-week regimen was supported in a phase I study (31), which indicated that three-week 9 mg/kg panitumumab and biweekly 6 mg/kg panitumumab have similar exposure and safety profiles. In addition, capecitabine and panitumumab administration every three weeks demonstrated efficacy and safety in a geriatric population in the Panel study (32). Despite these controversies, three-week mCAPIRI-P has several advantages including convenient oral administration, less frequent clinic attendance, and the absence of oxaliplatin-associated disturbing peripheral neuropathy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer

et al. 2023

View full text Add to dashboard Cite

IntroductionCapecitabine, irinotecan, and panitumumab (CAPIRI-P) is a controversial regimen for metastatic colorectal cancer, with concerns regarding the efficacy and toxicity. However, its toxicity profile has been improved with dose reduction, and concerns regarding efficacy have been extrapolated from other trials. This retrospective study reports the real-world effectiveness and safety of modified CAPIRI-P (mCAPIRI-P).Material and methodsAdvanced colorectal cancer patients receiving mCAPIPI-P in the first-line setting between July 2019 and December 2021 were analyzed. The progression-free survival on treatment (PFSOT) and overall survival (OS) were estimated using the Kaplan–Meier method, and the association with clinical and disease factors was analyzed using the Cox regression model. Serial changes in carcinoembryonic antigen (CEA) level and treatment toxicity were also evaluated.ResultsA total of 106 patients were included, of whom 97 (92%) and 31 (29%) had left-sided primary and unresectable liver-only disease, respectively. The median PFSOT and OS were 15.4 (95% CI 12.5–18.3) and 25.5 (95% CI 17.6–33.4) months, respectively. Sixteen (51.6%) and 10 (32.3%) liver-only disease patients underwent secondary liver treatment and R0 resection, respectively. In multivariable Cox regression, CEA responders (PFSOT: HR 0.53) and CEA normalization (PFSOT: HR 0.27; OS: HR 0.28) were independent favorable prognostic factors for PFSOT and OS. Grade ≥3 toxicity rate was 43%, mainly related to uncomplicated hematological toxicities.ConclusionThe real-world data show that mCAPIRI-P is safe and effective as the first-line treatment regimen for RAS wild-type advanced colorectal cancer and warrants further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…PANEL is a phase II study enrolling just 27 older patients (age ≥ 70 years) with wt RAS mCRC and treated with panitumumab plus capecitabine until disease progression or unacceptable toxicity as first-line therapy [ 36 ]. The majority of patients had an ECOG 1 (66.7%) and their median age was 78 years.…”

Section: Anti-egfr Inhibitors and Vunerable Patientsmentioning

confidence: 99%

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer

Rosati

Montrone

Pacilio

et al. 2022

JCM

View full text Add to dashboard Cite

Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients.

show abstract

Elderly Rectal Cancer: An Updated Review

Huang,

Shih,

Kao

2024

Curr Oncol Rep

View full text Add to dashboard Cite

First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

Cited by 6 publications

References 19 publications

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer

Elderly Rectal Cancer: An Updated Review

Contact Info

Product

Resources

About